Treatment Decision Making by Stage for Resectable NSCLC

EP: 1.Treatment Approaches for Early-Stage Lung Cancer

EP: 2.Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 3.Neoadjuvant/Perioperative Immunotherapy in NSCLC

EP: 4.Referral of Early-Stage NSCLC to Multidisciplinary Teams

EP: 5.Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 6.Updates in CheckMate-816 From ESMO 2023

EP: 7.AEGEAN Trial: Perioperative Approach in NSCLC

EP: 8.Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 9.CheckMate-77T Trial Results From ESMO 2023

Now Viewing

EP: 10.Treatment Decision Making by Stage for Resectable NSCLC

EP: 11.The Emerging Role of ctDNA in NSCLC Management

EP: 12.Addressing Gaps in Care for Non-Small Cell Lung Cancer

This is a video synopsis/summary of Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss the decision-making process for choosing between neoadjuvant, perioperative, or adjuvant therapy in patients with early-stage NSCLC. For stage III disease, there is a strong consensus that patients should receive some form of preoperative treatment due to the significant benefits demonstrated in clinical trials. However, the decision for stage II patients is more challenging.

At The University of Texas MD Anderson Cancer Center, there is a strong inclination to administer a neoadjuvant approach even in stage II patients, as it allows for the assessment of tumor biology and response to treatment at baseline and after surgery, which can be aligned with long-term outcomes. Additionally, patients generally tolerate treatment better before surgery rather than after. However, if a patient undergoes upfront surgery, an adjuvant chemotherapy and immunotherapy paradigm is available for nondriver mutations.

Factors influencing the decision include the surgeon's referral, the patient's willingness to undergo chemotherapy, and the potential benefits of neoadjuvant therapy, such as increased likelihood of receiving and completing systemic therapy, better tolerability, and the ability to assess tumor responsiveness to therapy using pathologic response.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.